-

01:24:23 PM

LIVE Real Time AIM Stock Market News

AIM - AIM ImmunoTech Inc

04/07/21 9:15 AM

AMEX : AIM

AIM ImmunoTech Announces Positive Safety Data in First Cohort of Phase 1 Clinical Study Investigating Intranasal Administration of Ampligen as a Potential Prophylaxis or Treatment for COVID-19 and Other Respiratory Viral Diseases

AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has completed dosing of Cohort 1 in a Phase 1 clinical study on the safety of AIM's drug Ampligen as an intranasal therapy, reporting no serious adverse events, and paving the way for

RHEA-AI

neutral

03/31/21 9:15 AM

AMEX : AIM

AIM ImmunoTech Reports 2020 Year-End Financial Results

AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the fiscal year ended December 31, 2020 and provides a business update. 2020 Financial Highlights As of December 31, 2020, AIM had cash, cash equivalents and marketable

RHEA-AI

neutral

03/22/21 8:45 AM

AMEX : AIM

AIM ImmunoTech Announces Addition of Single-Agent Ampligen Arm to Cancer Center's Ongoing Study in Cancer Patients with COVID-19

AIM ImmunoTech Inc. (NYSE American: AIM) today announced that the Institutional Review Board (IRB) of Roswell Park Comprehensive Cancer Center (Roswell Park) has approved a protocol amendment to Roswell Park's ongoing Phase 1/2a study evaluating the

RHEA-AI

neutral

03/11/21 7:00 AM

AMEX : AIM

AIM ImmunoTech to Present at the Q1 Virtual Investor Summit on March 24th

via InvestorWire - AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech, will be presenting at the Q1 Virtual Investor Summit. Event Q1 Investor Summit Date March 23-25th, 2021

RHEA-AI

neutral

03/10/21 6:55 AM

AMEX : AIM

AIM ImmunoTech to Participate at M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference

AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas K. Equels, AIM's Chief Executive Officer, has been invited to present at the Inaugural Emerging Growth Virtual Conference, presented by M Vest LLC and Maxim Group LLC. The

RHEA-AI

neutral

03/08/21 9:15 AM

AMEX : AIM

AIM ImmunoTech Announces First Healthy Subjects Dosed in Phase 1 Intranasal Ampligen Clinical Study

AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has dosed the first healthy subjects

RHEA-AI

neutral

03/04/21 6:50 AM

AMEX : AIM

AIM ImmunoTech to Present at the H.C. Wainwright Global Life Sciences Conference on March 9th

AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech, will be presenting at the H.C. Wainwright Life Sciences Conference to be held virtually between March 9-10, 2021. AIM's

RHEA-AI

neutral

02/24/21 9:15 AM

AMEX : AIM

AIM ImmunoTech's Subsidiary Receives Orphan Medicinal Product Designation by the European Medicines Agency for Ampligen to Treat Pancreatic Cancer

AIM ImmunoTech Inc. (NYSE American: AIM) today announced that its subsidiary, NV Hemispherx Biopharma Europe, has received formal notification from the European Commission (EC) approving the company's Orphan Medicinal Product Application for Ampligen

RHEA-AI

very positive

02/16/21 9:15 AM

AMEX : AIM

AIM ImmunoTech Announces Ethics Committee Approval to Commence Phase 1 Clinical Study of Ampligen as an Intranasal Therapy

AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has received approval from the required Ethics Committee in the Netherlands to commence its Phase 1 clinical study on the safety of AIM's drug Ampligen as an intranasal therapy, a

RHEA-AI

very positive

02/10/21 9:15 AM

AMEX : AIM

AIM ImmunoTech Announces the Expansion of its Pancreatic Cancer Program to Include New Patients in the Netherlands

AIM ImmunoTech Inc. (NYSE American: AIM) today announced that the Dutch Health and Youth Care Inspectorate (IGJ) has approved

RHEA-AI

very positive